|
|
 |
|
Viewing report
|
|
|
|
The China Pharmaceutical Market: A Strategic Opportunity Analysis
Pharmalicensing Ltd., Jan 2007, Pages: 100
China has become an attractive destination for R&D as new opportunities have emerged following its WTO (World Trade Organization) accession. Development has accelerated both industrially and scientifically, and today the Chinese pharmaceutical market is worth around $US12 billion.
Factors fuelling the developmental growth and attracting foreign investors to the area include low labor costs, high quality clinical data and an abundance of R&D collaborative opportunities and facilities.
Global biotechnology within China has also undergone significant growth, promising enormous potential for new companies. Biotechnology companies in the country have already grown quicker than pharmaceutical companies.
The report discusses the whole of the Chinese pharmaceutical market, taking readers through the history and current state of the healthcare system through to the regulations governing the country and its growing R&D capabilities. Detailing the driving forces behind the pharma market and including a full breakdown of the biopharma opportunities, including the contacts of active Chinese companies, the report is an essential resource to understand and access this lucrative market.
Reasons to purchase this report:
- Identify key partners
- Assess the current market opportunity
- Learn how newly implemented government changes have altered the face of the industry
- Understand the organization and success of clinical trials in China
- Create strategies for profitable market access into China
The Chinese government also plays an instrumental role in the pharmaceutical development of China. The introduction of WTO guidelines and protection for intellectual property rights has caused a shift in the company structures of China, forcing some to close business or enter into new collaborations.
Ideally suited for individuals wishing to introduce their companies into this emerging market or review the opportunities available, this report provides a perfect resource to identify the current pattern of the market and understand the regulations that operate within the country.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Emerging Clinical Trial Locations – China: Market Dynamics and the Changing Healthcare and Regulatory Environment
Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth
Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)
China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration
Innovative Drug Discovery in Emerging Markets
Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials
Chinese Pharmaceutical Industry: Strategies, Trends and Opportunities
China Pharma Outsourcing Annual Review 2010
Emerging Market for Clinical Trials in Russia - Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player
Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market
|
|
|
|
